Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Fabio D. Steffen, Iria Anne Jimenez, Yun Huang, Kerstin K. Rauwolf, Arijit Chakraborty, Shekhar Krishnan, Vaskar Saha, Beat Bornhauser, Jean-Pierre Bourquin

Blood (2023) 142 (Supplement 1): 417.

https://doi.org/10.1182/blood-2023-172885

Published: 2023

Journal Articles

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Arijit Chakraborty, Parag Das, Manash Pratim Gogoi, Tanima Dey, Fabio D. Steffen, Sangramjit Basu, Debdutta Ganguli, Debjani Ghosh, Niharendu Ghara, Subhajit Kundu, Abhirupa Kar, Beat Bornhauser, Jean-Pierre Bourquin, Vaskar Saha, Shekhar Krishnan

Blood (2023) 142 (Supplement 1): 4244.

https://doi.org/10.1182/blood-2023-185989

Published: 2023

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Blood (2021) 138 (Supplement 1): 1231.

https://doi.org/10.1182/blood-2021-145476

Published: 2021

Journal Articles

A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)

Andrea Biondi, MD, Virginie Gandemer, MDPhD, Myriam Campbell, MD, Anders Castor, MD PhD, Rob Pieters, MD PhD, Paola De Lorenzo, PhD, Veronica Leoni, MD, Jan Stary, Gabriele Escherich, MD, Chi Kong Li, MD, Giovanni Cazzaniga, PhD, Helene Cave, PharmD, PhD, Silja Roettgers, PhD, Valentino Conter, MD, Vaskar Saha, MD PhD, Martin Schrappe, MD PhD, Maria Grazia Valsecchi, PhD

Blood (2017) 130 (Supplement 1): 97.

https://doi.org/10.1182/blood.V130.Suppl_1.97.97

Published: 2017

Journal Articles

CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Blood (2017) 130 (Supplement 1): 98.

https://doi.org/10.1182/blood.V130.Suppl_1.98.98

Published: 2017

Journal Articles

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Blood (2017) 129 (11): e26–e37.

https://doi.org/10.1182/blood-2016-09-738070

Published: 2017

Includes: Supplemental data

Journal Articles

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

Blood (2016) 128 (7): 911–922.

https://doi.org/10.1182/blood-2016-03-704973

Published: 2016

Includes: Supplemental data

Journal Articles

Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia

Suzanne M. Johnson, Clare Dempsey, Amy Chadwick, Stephanie Harrison, Jizhong Liu, Yujun Di, Owen J. McGinn, Marco Fiorillo, Federica Sotgia, Michael P. Lisanti, Mayur Parihar, Shekhar Krishnan, Vaskar Saha

Blood (2016) 128 (3): 453–456.

https://doi.org/10.1182/blood-2015-12-688051

Published: 2016

Journal Articles

EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications

Claire Schwab, Sarra L. Ryan, Lucy Chilton, Alannah Elliott, James Murray, Stacey Richardson, Christopher Wragg, John Moppett, Michelle Cummins, Oliver Tunstall, Catriona A. Parker, Vaskar Saha, Nicholas Goulden, Ajay Vora, Anthony V. Moorman, Christine J. Harrison

Blood (2016) 127 (18): 2214–2218.

https://doi.org/10.1182/blood-2015-09-670166

Published: 2016

Includes: Supplemental data

Journal Articles

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Blood (2015) 126 (23): 1414.

https://doi.org/10.1182/blood.V126.23.1414.1414

Published: 2015

Journal Articles

Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

Catriona Anne Parker, PhD, Marie Reeves, MSc, Sharon Love, MSc, Jeremy Hancock, PhD, Peter M Hoogerbrugge, MD PhD, Rosemary Sutton, Tom Revesz, MD, Vaskar Saha, PhD FRCP, FRCPath

Blood (2015) 126 (23): 1294.

https://doi.org/10.1182/blood.V126.23.1294.1294

Published: 2015

Journal Articles

Metabolic Reprogramming of Bone Marrow Stromal Cells By Leukemic Extracellular Vesicles in Acute Lymphoblastic Leukemia (ALL)

Suzanne M. Johnson, Clare Dempsey, Amy Chadwick, Stephanie Harrison, Jizhong Liu, Yujun Di, Owen McGinn, Mayur Parihar, Federica Sotgia, Michael Lisanti, Shekhar Krishnan, Vaskar Saha, PhD FRCP, FRCPath

Blood (2015) 126 (23): 1430.

https://doi.org/10.1182/blood.V126.23.1430.1430

Published: 2015

Journal Articles

Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study

Blood (2014) 124 (21): 3782.

https://doi.org/10.1182/blood.V124.21.3782.3782

Published: 2014

Journal Articles

IKZF1 status as a prognostic feature in BCR-ABL1– positive childhood ALL

Arian van der Veer, Marketa Zaliova, Federica Mottadelli, Paola De Lorenzo, Gertruuy te Kronnie, Christine J. Harrison, Hélène Cavé, Jan Trka, Vaskar Saha, Martin Schrappe, Rob Pieters, Andrea Biondi, Maria Grazia Valsecchi, Martin Stanulla, Monique L. den Boer, Giovanni Cazzaniga

Blood (2014) 123 (11): 1691–1698.

https://doi.org/10.1182/blood-2013-06-509794

Published: 2014

Includes: Supplemental data

Journal Articles

The Clinical Relevance Of Genetics In Predicting Outcome After a First Relapse In Children With B-Cell Precursor Acute Lymphoblastic Leukaemia

Anthony V. Moorman, Amy Erhorn, Catriona Parker, Rosemary Sutton, Claire Schwab, BSc, Nicola C Venn, Peter M. Hoogerbrugge, Tamas Revesz, Vaskar Saha, Christine J Harrison, PhD

Blood (2013) 122 (21): 2566.

https://doi.org/10.1182/blood.V122.21.2566.2566

Published: 2013

Journal Articles

Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study

Giovanni Cazzaniga, Martin Schrappe, Paola de Lorenzo, Anders Castor, Giovanna Lucchini, Virginie Gandemer, Rob Pieters, MD, PhD, Jan Stary, Gabriele Escherich, Jeremy Hancock, Maurizio Arico', Silja Röttgers, Vaskar Saha, Andrea Biondi, MD, Maria Grazia Valsecchi

Blood (2012) 120 (21): 1467.

https://doi.org/10.1182/blood.V120.21.1467.1467

Published: 2012

Journal Articles

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Caroline YK Fong, Catriona Anne Parker, Adiba Hussain, Jizhong Liu, Monika Essink, Hans Juergen Kuehnel, Donna L Lancaster, Genevieve Pridham, Debbie Payne, Charlotte O'Horo, Shekhar Krishnan, Jeremy Hancock, Nicholas Goulden, Anthony V. Moorman, Sue Richards, Ajay J Vora, Vaskar Saha, Ashish Narayan Masurekar

Blood (2011) 118 (21): 2573.

https://doi.org/10.1182/blood.V118.21.2573.2573

Published: 2011

Journal Articles

Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL). the EsPhALL Study

Andrea Biondi, MD, Martin Schrappe, MD, Paola Di Lorenzo, Anders Castor, Giovanna Lucchini, Virginie Gandemer, Rob Pieters, Jan Stary, M.D., Gabriele Escherich, Myriam Campbell, Ci Kong-Li, Ajay J Vora, Gudmar Lonnerholm, Maurizio Arico‘, Jochen Harbott, Vaskar Saha, Maria Grazia Valsecchi

Blood (2011) 118 (21): 873.

https://doi.org/10.1182/blood.V118.21.873.873

Published: 2011

Journal Articles

RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia

Blood (2011) 118 (3): 638–649.

https://doi.org/10.1182/blood-2010-09-307330

Published: 2011

Includes: Supplemental data

NARROW

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)

CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia

EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

Metabolic Reprogramming of Bone Marrow Stromal Cells By Leukemic Extracellular Vesicles in Acute Lymphoblastic Leukemia (ALL)

Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study

IKZF1 status as a prognostic feature in BCR-ABL1– positive childhood ALL

The Clinical Relevance Of Genetics In Predicting Outcome After a First Relapse In Children With B-Cell Precursor Acute Lymphoblastic Leukaemia

Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL). the EsPhALL Study

RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only